Prostate Cancer / 2012 / Article / Tab 2

Research Article

Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men

Table 2

Frequency of genotypes among South African and Senegalese prostate cancer cases and controls.

South Africa Senegal
GenotypesWhite MixedBlackCombinedSenegalese
GenesControls
( 4)
Cases
( )
Controls ( )Cases
( )
Controls ( )Cases
( )
Controls ( )Cases
( )
Controls ( )Cases
( )

CYP3A4 (rs2740574)
 AA122
(91.0%)
84
(70.0%)
117 (70.1%)82 (39.6%)2
(10.0%)
9
(36.0%)
241 (75.1%)175 (49.7%)21
(7.5%)
6
(7.1%)
 AG12
(9.0%)
34 (28.3%)49 (29.3%)111 (53.6%)15 (75.0%)16 (64.0%)76 (23.7%)161 (45.7%)91 (32.3%)40 (47.6%)
 GG0
(0%)
2
(1.7%)
1
(0.6%)
14
(6.8%)
3
(15.0%)
0
(0%)
4
(1.2%)
16
(4.6%)
170 (60.3%)38 (45.2%)

CYP3A5 (rs776746)
 GG113 (84.3%)95 (79.2%)58 (34.7%)58 (28.0%)1
(5.0%)
1
(4.0%)
172 (53.6%)154 (43.8%)14
(5.3%)
4
(5.1%)
 AG18 (13.4%)22 (18.3%)72 (43.1%)106 (51.2%)5
(25.0%)
5
(20.0%)
95 (29.6%)133 (37.8%)66 (25.1%)20 (25.3%)
 AA 3
(2.3%)
3
(2.5%)
37 (22.2%)43 (20.8%)14 (70.0%)19 (76.0%)54 (16.8%)65 (18.4%)183 (69.6%)55 (69.6%)

SRD5A2 V89L (rs523349)
 GG56 (41.8%)61 (50.8%)96 (57.5%)131 (63.3%)5
(25.0%)
16 (64.0%)157 (48.9%)208 (59.1%)26 (12.2%)10 (14.1%)
 CG70 (52.2%)51 (42.5%)65 (38.9%)71 (34.3%)7
(35.0%)
7
(28.0%)
142 (44.2%)129 (36.6%)61 (28.5%)10 (14.1%)
 CC 8
(6.0%)
8
(6.7%)
6
(3.6%)
5
(2.4%)
8
(40.0%)
2
(8.0%)
22
(6.9%)
15
(4.3%)
127 (59.4%)51 (71.8%)

SRD5A2 A49T (rs9282858)
 GG107 (79.8%)90 (75.0%)127 (76.0%)120 (58.0%)10 (50.0%)17 (68.0%)244 (76.0%)227 (64.5%)278 (100.0%)75 (100.0%)
 GA27 (20.2%)30 (25.0%)40 (24.0%)87 (42.0%)10 (50.0%)8
(32.0%)
77 (24.0%)125 (35.5%)0
(0%)
0
(0.0%)

, for each polymorphism when comparing across each of the respective population groups for cases or for controls.
Some participants had missing genotype data. The numbers and percentages shown are for the available information.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.